Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins

Prostate

Volumn 72, Issue 5, 2012, Pages 555-565

  Stangelberger, Anton ^a,b   Schally, Andrew V ^b,c,d   Rick, Ferenc G ^b,c,d   Varga, Jozsef L ^b,c,d   Baker, Benjamin ^b   Zarandi, Marta ^b,c,d   Halmos, Gabor ^b,c,d,e  

^a Landesklinikum Baden ^*  (Austria)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c South Florida Veterans Affairs Foundation for Research and Education   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

androgen independent prostate cancer; apoptosis; GHRH antagonist; p21; p53

Indexed keywords

ANTINEOPLASTIC AGENT; CETRORELIX; CYCLIN DEPENDENT KINASE INHIBITOR 1A; D 20762; GROWTH HORMONE RELEASING FACTOR RECEPTOR; HORMONE RECEPTOR BLOCKING AGENT; MUTANT PROTEIN; MZJ 7138; PROTEIN P53; UNCLASSIFIED DRUG;

ANDROGEN DEPRIVATION THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; WILD TYPE;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MALE; MICE; MICE, NUDE; MUTANT PROTEINS; NEOPLASM TRANSPLANTATION; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS P21(RAS); SERMORELIN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84857137088     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21458     Document Type: Article

References (56)

1. Feldman BJ, Feldman D,. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1 (1): 34-45.
2. Schally AV,. New approaches to the therapy of various tumors based on peptide analogues. Horm Metab Res 2008; 40 (5): 315-322.
3. Schally AV, Varga JL, Engel JB,. Antagonists of growth-hormone-releasing hormone: An emerging new therapy for cancer. Nat Clin Pract Endocrinol Metab 2008; 4 (1): 33-43.
4. Schally AV, Varga JL,. Antagonists of growth hormone-releasing hormone in oncology. Comb Chem High Throughput Screen 2006; 9 (3): 163-170.
5. Letsch M, Schally AV, Busto R, Bajo AM, Varga JL,. Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers. Proc Natl Acad Sci USA 2003; 100 (3): 1250-1255.
6. Heinrich E, Schally AV, Buchholz S, Rick FG, Halmos G, Mile M, Groot K, Hohla F, Zarandi M, Varga JL,. Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138. Prostate 2008; 68 (16): 1763-1772.
7. Halmos G, Schally AV, Czompoly T, Krupa M, Varga JL, Rekasi Z,. Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer. J Clin Endocrinol Metab 2002; 87 (10): 4707-4714.
8. Stangelberger A, Schally AV, Varga JL, Hammann BD, Groot K, Halmos G, Cai RZ, Zarandi M,. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers. Prostate 2005; 64 (3): 303-315.
9. Wallace-Brodeur RR, Lowe SW,. Clinical implications of p53 mutations. Cell Mol Life Sci 1999; 55 (1): 64-75.
10. Vikhanskaya F, Lee MK, Mazzoletti M, Broggini M, Sabapathy K,. Cancer-derived p53 mutants suppress p53-target gene expressionPotential mechanism for gain of function of mutant p53. Nucleic Acids Res 2007; 35 (6): 2093-2104.
11. Smith ND, Rubenstein JN, Eggener SE, Kozlowski JM,. The p53 tumor suppressor gene and nuclear protein: Basic science review and relevance in the management of bladder cancer. J Urol 2003; 169 (4): 1219-1228.
12. Pisters LL, Pettaway CA, Troncoso P, McDonnell TJ, Stephens LC, Wood CG, Do KA, Brisbay SM, Wang X, Hossan EA, Evans RB, Soto C, Jacobson MG, Parker K, Merritt JA, Steiner MS, Logothetis CJ,. Evidence that transfer of functional p53 protein Results: in increased apoptosis in prostate cancer. Clin Cancer Res 2004; 10 (8): 2587-2593.
13. Navone NM, Rodriquez-Vargas MC, Benedict WF, Troncoso P, McDonnell TJ, Zhou JH, Luthra R, Logothetis CJ,. TabBo: A model reflecting common molecular features of androgen-independent prostate cancer. Clin Cancer Res 2000; 6 (3): 1190-1197.
14. Zellweger T, Ninck C, Bloch M, Mirlacher M, Koivisto PA, Helin HJ, Mihatsch MJ, Gasser TC, Bubendorf L,. Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer 2005; 113 (4): 619-628.
15. Bossi G, Lapi E, Strano S, Rinaldo C, Blandino G, Sacchi A,. Mutant p53 gain of function: Reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene 2006; 25 (2): 304-309.
16. Scian MJ, Stagliano KE, Ellis MA, Hassan S, Bowman M, Miles MF, Deb SP, Deb S,. Modulation of gene expression by tumor-derived p53 mutants. Cancer Res 2004; 64 (20): 7447-7454.
17. Blagosklonny MV, Trostel S, Kayastha G, Demidenko ZN, Vassilev LT, Romanova LY, Bates S, Fojo T,. Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors. Cancer Res 2005; 65 (16): 7386-7392.
18. Lee JT, Lehmann BD, Terrian DM, Chappell WH, Stivala F, Libra M, Martelli AM, Steelman LS, McCubrey JA,. Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle 2008; 7 (12): 1745-1762.
19. Isaacs WB, Carter BS, Ewing CM,. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 1991; 51 (17): 4716-4720.
20. Li R, Hannon GJ, Beach D, Stillman B,. Subcellular distribution of p21 and PCNA in normal and repair-deficient cells following DNA damage. Curr Biol 1996; 6 (2): 189-199.
21. Martinez LA, Yang J, Vazquez ES, Rodriguez-Vargas Mdel C, Olive M, Hsieh JT, Logothetis CJ, Navone NM,. p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. Carcinogenesis 2002; 23 (8): 1289-1296.
22. Janicke RU, Sohn D, Essmann F, Schulze-Osthoff K,. The multiple battles fought by anti-apoptotic p21. Cell Cycle 2007; 6 (4): 407-413.
23. Kim CG, Choi BH, Son SW, Yi SJ, Shin SY, Lee YH,. Tamoxifen-induced activation of p21Waf1/Cip1 gene transcription is mediated by Early Growth Response-1 protein through the JNK and p38 MAP kinase/Elk-1 cascades in MDA-MB-361 breast carcinoma cells. Cell Signal 2007; 19 (6): 1290-1300.
24. Lin PY, Fosmire SP, Park SH, Park JY, Baksh S, Modiano JF, Weiss RH,. Attenuation of PTEN increases p21 stability and cytosolic localization in kidney cancer cells: A potential mechanism of apoptosis resistance. Mol Cancer 2007; 6: 16.
25. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ Jr, Kohn KW,. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997; 57 (19): 4285-4300.
26. Rohlff C, Blagosklonny MV, Kyle E, Kesari A, Kim IY, Zelner DJ, Hakim F, Trepel J, Bergan RC,. Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21(waf1/cip1). Prostate 1998; 37 (1): 51-59.
27. Levkau B, Koyama H, Raines EW, Clurman BE, Herren B, Orth K, Roberts JM, Ross R,. Cleavage of p21Cip1/Waf1 and p27Kip1 mediates apoptosis in endothelial cells through activation of Cdk2: Role of a caspase cascade. Mol Cell 1998; 1 (4): 553-563.
28. Fizazi K, Martinez LA, Sikes CR, Johnston DA, Stephens LC, McDonnell TJ, Logothetis CJ, Trapman J, Pisters LL, Ordonez NG, Troncoso P, Navone NM,. The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer. Clin Cancer Res 2002; 8 (3): 775-781.
29. Aaltomaa S, Lipponen P, Eskelinen M, Ala-Opas M, Kosma VM,. Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer. Prostate 1999; 39 (1): 8-15.
30. Baretton GB, Klenk U, Diebold J, Schmeller N, Lohrs U,. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: Prognostic significance of p21/WAF1/CIP1 expression. Br J Cancer 1999; 80 (3-4): 546-555.
31. Lacombe L, Maillette A, Meyer F, Veilleux C, Moore L, Fradet Y,. Expression of p21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy. Int J Cancer 2001; 95 (3): 135-139.
32. Rick FG, Schally AV, Block NL, Nadji M, Szepeshazi K, Zarandi M, Vidaurre I, Perez R, Halmos G, Szalontay L,. Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia. Proc Natl Acad Sci USA 2011; 108 (9): 3755-3760.
33. Kanashiro CA, Schally AV, Groot K, Armatis P, Bernardino AL, Varga JL,. Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin. Proc Natl Acad Sci USA 2003; 100 (26): 15836-15841.
34. Varga JL, Schally AV, Horvath JE, Kovacs M, Halmos G, Groot K, Toller GL, Rekasi Z, Zarandi M,. Increased activity of antagonists of growth hormone-releasing hormone substituted at positions 8, 9 and 10. Proc Natl Acad Sci USA 2004; 101 (6): 1708-1713.
35. Bajusz S, Csernus VJ, Janaky T, Bokser L, Fekete M, Schally AV,. New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues. Int J Pept Protein Res 1988; 32 (6): 425-435.
36. McDonnell TJ, Navone NM, Troncoso P, Pisters LL, Conti C, von Eschenbach AC, Brisbay S, Logothetis CJ,. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol 1997; 157 (2): 569-574.
37. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, von Eschenbach AC, Conti CJ,. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993; 85 (20): 1657-1669.
38. Stapleton AM, Timme TL, Gousse AE, Li QF, Tobon AA, Kattan MW, Slawin KM, Wheeler TM, Scardino PT, Thompson TC,. Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Clin Cancer Res 1997; 3 (8): 1389-1397.
39. Carroll AG, Voeller HJ, Sugars L, Gelmann EP,. p53 oncogene mutations in three human prostate cancer cell lines. Prostate 1993; 23 (2): 123-134.
40. Letsch M, Schally AV, Stangelberger A, Groot K, Varga JL,. Antagonists of growth hormone-releasing hormone (GH-RH) enhance tumour growth inhibition induced by androgen deprivation in human MDA-Pca-2b prostate cancers. Eur J Cancer 2004; 40 (3): 436-444.
41. Stangelberger A, Schally AV, Zarandi M, Heinrich E, Groot K, Havt A, Kanashiro CA, Varga JL, Halmos G,. The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers. Prostate 2007; 67 (12): 1339-1353.
42. Leuschner C, Enright FM, Gawronska-Kozak B, Hansel W,. Human prostate cancer cells and xenografts are targeted and destroyed through luteinizing hormone releasing hormone receptors. Prostate 2003; 56 (4): 239-249.
43. 2+-dependent pathway. Proc Natl Acad Sci USA 2005; 102 (9): 3435-3440.
44. Greenblatt MS, Bennett WP, Hollstein M, Harris CC,. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54 (18): 4855-4878.
45. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ, Lucia MS,. Molecular characterization of human prostate carcinoma cell lines. Prostate 2003; 57 (3): 205-225.
46. Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM, Johnston D, Pollack A, Pathak S, von Eschenbach AC, Logothetis CJ,. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res 1997; 3 (12 Pt 1): 2493-2500.
47. Natsume T, Kobayashi M, Fujimoto S,. Association of p53 gene mutations with sensitivity to TZT-1027 in patients with clinical lung and renal carcinoma. Cancer 2001; 92 (2): 386-394.
48. Werner H, Karnieli E, Rauscher FJ, LeRoith D,. Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci USA 1996; 93 (16): 8318-8323.
49. Lee YI, Lee S, Das GC, Park US, Park SM,. Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma. Oncogene 2000; 19 (33): 3717-3726.
50. Cronauer MV, Schulz WA, Burchardt T, Ackermann R, Burchardt M,. Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines. Oncogene 2004; 23 (20): 3541-3549.
51. Hu YX, Watanabe H, Ohtsubo K, Yamaguchi Y, Ha A, Motoo Y, Okai T, Sawabu N,. Infrequent expression of p21 is related to altered p53 protein in pancreatic carcinoma. Clin Cancer Res 1998; 4 (5): 1147-1152.
52. Tu Y, Wu W, Wu T, Cao Z, Wilkins R, Toh BH, Cooper ME, Chai Z,. Antiproliferative autoantigen CDA1 transcriptionally up-regulates p21(Waf1/Cip1) by activating p53 and MEK/ERK1/2 MAPK pathways. J Biol Chem 2007; 282 (16): 11722-11731.
53. Meng LH, Kohn KW, Pommier Y,. Dose-response transition from cell cycle arrest to apoptosis with selective degradation of Mdm2 and p21WAF1/CIP1 in response to the novel anticancer agent, aminoflavone (NSC 686,288). Oncogene 2007; 26 (33): 4806-4816.
54. Stangelberger A, Schally AV, Varga JL, Zarandi M, Cai RZ, Baker B, Hammann BD, Armatis P, Kanashiro CA,. Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signalling. Eur J Cancer 2005; 41 (17): 2735-2744.
55. Hohla F, Schally AV, Szepeshazi K, Varga JL, Buchholz S, Koster F, Heinrich E, Halmos G, Rick FG, Kannadka C, Datz C, Kanashiro CA,. Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel. Proc Natl Acad Sci USA 2006; 103 (39): 14513-14518.
56. Buchholz S, Schally AV, Engel JB, Hohla F, Heinrich E, Koester F, Varga JL, Halmos G,. Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel. Proc Natl Acad Sci USA 2007; 104 (6): 1943-1946.